Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue 2, 2001, Pages 112-116

  Sonmez, Alper ^a   Kisa, Ucler ^b   Uckaya, Gokhan ^a   Eyileten, Tayfun ^a   Comert, Bilgin ^a   Koc, Bayram ^a   Kocabalkan, Fikri ^a   Ozata, Metin ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

AT1 receptor antagonism; Leptin; Phytohaemagglutinin; Primary hypertension; T cell

Indexed keywords

ANTIHYPERTENSIVE AGENT; LEPTIN; LOSARTAN;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; IMMUNOLOGY; MALE; MIDDLE AGED; T LYMPHOCYTE;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; LEPTIN; LOSARTAN; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0035382651     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2001.011     Document Type: Article

References (40)

1. Agata J, Masuda A, Takada M. High plasma immunoreactive leptin level in essential hypertension. Hypertension 1997;10:1171-4.
2. Suter PM, Locher R, Hasler E, Vetter W. Is there a role for the ob gene product leptin in essential hypertension. Am J Hypertens 1998;11:1305-11.
3. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31:409-14.
4. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-23.
5. Jones BH, Strandridge MK, Taylor JW, Moustaid N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J physiol 1997;273: R236-R242.
6. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999;17:555-60.
7. Karlsson C, Lindell K, Ottoson M, Sjöström L, Carlsson LMS. Human adipose tissue expresses angiotensinogen and requires for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925-9.
8. Cooper R, Forrester T, Ogunbiyi O, Muffinda J. Angiotensinogen levels and obesity in four black populations. J Hypertens 1998;16:571-5.
9. Umemura S, Nyui N, Tamura K et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997;10:629-33.
10. Schorr U, Blanschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998;16:1475-80.
11. Uckaya G, Ozata M, Sonmez A et al. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res 1999;31:435-8.
12. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999;84:3686-95.
13. Torpy DJ, Bornstein SR, Taylor W, Tauchnitz R, Gordon RD. Leptin levels are suppressed in primary aldosteronism. Horm Metab Res 1999;31:533-6.
14. Malendowicz LK, Tortorella C, Nowak KW, Nussdorfer GG, Hochol A, Majchrzak M. Leptin prolonged administration inhibits the growth and glucocorticoid secretion of rat adrenal cortex. Endocr Res 2000;26:141-52.
15. Flier JS. Lowered leptin slims immune response. Nature Med 1998;4:1124-5.
16. Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosupression. Nature 1998;394:897-901.
17. Martin RC, Santos AJ, Goberna RS, Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 2000;199:15-24.
18. Suzuki H, Shibata H, Murakami M, Sato A, Naito M, Ischihara A. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: Comparison of platelets and mononuclear leukocytes. J Endocrinol 1995;42(suppl 1):15-22.
19. Hahn AWA, Jonas U, Fritz R. Activation of human peripheral monocytes by angiotensin II. FEBS Letters 1994;347:178-80.
20. Kunert RJ, Stepien H, Komorowski J, Pawlikowski M. Stimulatory effect of angiotensin II on the proliferation of mouse spleen lymphocytes in vitro is mediated via both types of angiotensin II receptors. Biochem Biophys Res Commun 1994;198:1034-9.
21. Gomez RA, Norling LL, Wilfong N, Isakson P. Leukocytes synthesize angiotensinogen. Hypertension 1993;21:470-5.
22. Martinez A, Buendia E, Carreras L, Font I, Mestre M, Rama H. Humoral and cellular immunological abnormalities in hypertensive patients. J Clin Hypertens 1985;1:153-60.
23. Takeichi N, Suzuki K, Okayashu H, Kobayashi H. Immunological depression in spontaneous hypertensive rats. Clin Exp Immunol 1980;40:120-6.
24. Pascual VH, Oparil S, Eldridge JH, Jin H, Bost KL, Pascual DW. Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation. Am J Physiol 1992;262(1 Pt 2):R1-7.
25. Shasha SM, Shasha U, Kristal B, Barzilai M, Steinberger O, Shkolnik T. The proliferative response of T lymphocytes to mitogenic lectins in essential hypertension. Nephron 1991;58:413-7.
26. Fannon LD, Braylan RC, Phillips MI. Alterations of lymphocyte populations during development in the spontaneously hypertensive rat. J Hypertens 1992;10:629-34.
27. Sharma N, Koicha M, Varma S, Kumari S, Ganguly NK, Sharma BK. Alteration of peripheral blood lymphocyte subsets in essential hypertension. Can J Cardiol 1996;12:657-61.
28. Kristensen BO. Increased serum levels of immunglobulins in untreated and treated essential hypertension. Acta Med Scand 1978;203:49-54.
29. Gudbrandsson T, Herlitz H, Lindholm L, Nilson LA. Immunological changes in patients with previous malignant essential hypertension. Lancet 1981;1:406-8.
30. Dzielak DJ. Immune mechanisms in experimental and essential hypertension. Am Physiol 1991;260(3 Pt 2):R459-67.
31. Fu MLX. Do immune system changes have a role in hypertension? J Hypertens 1995;13:1259-65.
32. Pawelec G, Adibzadeh M, Solana R, Beckman I. The T cell in the aging individual. Mech Aging Dev 1997;93:35-45.
33. Kristensen BO, Solling K. Serum concentrations of immunoglobulins and free light chains before and after vascular events in essential hypertension. Acta Med Scand 1983;13:15-20.
34. Lijnen P, Fagard R, Petrov V. Proliferation of human peripheral blood mononuclear cells during calcium channel blockade. Am J Hypertens 1998;11:1461-8.
35. Shasha SM, Nusam D, Labin L, Kriatal B. Effect of converting enzyme inhibitor Captopril on T-cell functions in essential hypertension. Nephron 1991;59:586-90.
36. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;24:2413-46.
37. Boyum A. Isolation of leukocytes from human blood. Scand J Lab Invest 1968;21(suppl 97):9-29.
38. Olsen F, Rasmussen S. Delayed hypersensitivity and borderline essential hypertension. Acta Pathol Microbiol Scand 1977;85:196-9.
39. Simon MR, Weinstock JV, Morrell RM, Roi LD, Howard LM. Captopril enhances in vitro human lymphocyte thymidine incorporation. Agents Actions 1984;15:525-8.
40. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.